PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA)
PLASMA Trial: Phospholipase Levels And Serological Markers of Atherosclerosis: A Dose-Response Clinical Pharmacology Study of A-002 In Subjects With Stable Coronary Artery Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Dnepropetrovs'k, Ukraine, 49027
- Dnipropetrovs'k State Medical Academy
-
Kharkiv, Ukraine, 61039
- Institute of Therapy of AMS
-
Khirkov, Ukraine, 61018
- Central Clinical Hospital "Ukrzaliznysti"
-
Kviv, Ukraine, 03680
- Strazhesko Institute of Cardiology AMS
-
Kyiv, Ukraine, 01023
- Kiev Central Hospital #1
-
Kyiv, Ukraine, 01103
- City Clinical Hospital No 12
-
Kyiv, Ukraine, 02175
- Scientific Centre of Endocrine Surgery
-
Kyiv, Ukraine, 03680
- Strazhesko Institute of Cardiology AMS
-
Kyiv, Ukraine, 04114
- Institute of Gerontology AMS
-
Kyiv, Ukraine, 04114
- Institute of Gerontology
-
L'viv, Ukraine, 79015
- L'viv Regional State Clinical Treatment and Diagnostics
-
Zaporizhzhya, Ukraine, 69108
- Hospital of "Radioprylad" Plant
-
-
03680
-
Kyiv, 03680, Ukraine
- Strazhesko Institute of Cardiology AMS
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36608
- Mobile Heart Specialists
-
-
Arizona
-
Scottsdale, Arizona, United States, 85260
- Sonoran Health Specialists
-
-
Arkansas
-
Hot Springs, Arkansas, United States, 71913
- Central Arkansas Research
-
-
Florida
-
Ft. Lauderdale, Florida, United States, 33316
- Broward General Medical Center
-
Hudson, Florida, United States
-
Port Charlotte, Florida, United States, 339521
- Charlotte Cardiovascuar Research
-
Tampa, Florida, United States, 33609
- Florida Cardiovascular Institute
-
-
Georgia
-
Augusta, Georgia, United States, 30901
- Augusta Cardiology Clinic, PC
-
-
Kentucky
-
Louisville, Kentucky, United States, 40207
- Louisville Cardiology Medical Group
-
-
Maine
-
Auburn, Maine, United States, 04210
- Maine Research Associates
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- University of Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
New York
-
Binghamton, New York, United States, 13901
- United Medical Associates
-
Endwell, New York, United States, 13760
- Regional Clinical Research, Inc.
-
Syracuse, New York, United States, 13210
- Cardiology, PC
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73132
- Oklahoma Cardiovascular and Hypertension Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18105
- LeHigh Valley Hospital
-
Camp Hill, Pennsylvania, United States
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57701
- Black Hills Clinical Research Center
-
-
Texas
-
Austin, Texas, United States, 78705
- Austin Heart
-
Dallas, Texas, United States, 75230
- Cardiopulmonary Research Science and Technology Institute
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Clinical Research Associates of Tidewater
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53715
- Winsconin Heart, SC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects are eligible for inclusion if they meet the following inclusion criteria:
- Men and women > 18 years of age
- Written informed consent from the subject
- Stable CAD
- Stable medical condition, will be compliant and able to comply with the requirements of the protocol
Exclusion Criteria:
- Subjects must NOT meet any of the following exclusion criteria:
- Planned CABG
- Hospitalization for acute coronary syndrome if troponin level is >0.1 ng/mL in the preceding 6 weeks
- Hospitalization for ST-segment acute myocardial infarction (STEMI) in the preceding 12 weeks
- Subjects with chronic inflammatory disease (e.g., RA), inflammatory bowel disease, recent (12 weeks) systemic or localized infection (the latter requiring clinical intervention), or major surgery
- hs-CRP >15 mg/L repeated on at least 2 occasions >24 hours apart due to non-cardiovascular systemic inflammatory conditions (e.g., rheumatoid disease)
- Acute or chronic heart failure as defined by the NYHA classification as functional Class III or Class IV
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Comparison of active and placebo treatments with respect to change from Baseline to Week 8 in sPLA2 levels and activity.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Comparison of active and placebo treatments with respect to change in: Inflammatory markers, lipid and biochemical parameters, and LDL and HDL subclasses.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AN-CVD-2221
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.